ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2770

Polymyalgia Rheumatica Relapse and “Silence” Large Vessel Vasculitis. Is There Any Association?

Stavros Chrysidis1, Philip Rask Lage-Hansen1 and Andreas P. Diamantopoulos2, 1Department of Rheumatology, Hospital of Southwest Denmark, Esbjerg, Denmark, 2Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: giant cell arteritis, large vessel vasculitis, Polymyalgia rheumatica and ultrasound

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Vasculitis

Session Type: Abstract Submissions (ACR)

Background/Purpose

Large Vessel Vasculitis (LVV) can present with heterogeneous clinical manifestations, which range from general symptoms (fever, loss of weight) to the classic symptoms of  Giant Cells Arteritis (GCA)  (headache, jaw claudication, visual manifestations). Around 40% of GCA  patients have concomitant Polymyalgia Rheumatica (PMR) and up to 40% of PMR  patients have a positive biopsy of the temporal artery (TAB).

Studies evaluating ultrasound (US) as a diagnostic tool in GCA have reported a high sensivity and specificity.

The aim of this study was to investigate the association between disease’s relapse and co-existing “silence” LVV in patients with pure PMR.

Methods

Patients with PMR who relapsed under corticosteroid (CS) tapering In Esbjerg Hospital, Denmark in the period of April 2013 to June 2014 have been prospectively included. In patients with PMR who relapsed under corticosteroid (CS) tapering,  US examination of temporal (AT), axillary (AA), subclavian (AS) and carotid (AC) arteries was performed. US images were recorded and evaluated by an ultrasonographer experienced on vascular ultrasound (AD), who was blinded to patients’ clinical and laboratory data.

US was considered positive when a homogeneous hypoechoic thickness >1.5 mm in AC and AS and >1mm in AA, in transverse and longitudinal view was observed.  For the AT, the typical sign of halo (arterial wall swelling in transverse and longitudinal view) was considered as vasculitis. Relapse was defined as the reappearance of PMR clinical symptoms in addition to elevated ESR or CRP (ESR> 40 mm/h, CRP>10mg/lt) or persistent increased CRP/SR without any other explanation. All patients with positive US findings underwent a TAB.

Results

On a period of 14 months, 17 patients had been evaluated. All patients fulfilled the Bird’s classifications criteria for PMR and all the patients responded appropriately to CS treatment at baseline. None of the patients had GCA- related clinical symptoms either on baseline or during the relapse. No significant differences were observed between the two groups of patients (PMR + LVV and PMR – LVV) in age, diseases duration, initial CRP/SR levels and initial CS dose (prednisolon 15-25mg).

Seven out of 17 (41%) patients had ultrasonographic sign of vasculitis. All patients had affection of the AA (6 of them bilateral), 3 of the AS, 1 of the AT none of the AC. The patient with the positive US of the AT was the only who had a positive TAB.

Conclusion

In our study, the relationship between PMR relapse and concomitant “silence” LVV has been evaluated. More than one-third of PMR patients who relapsed had a co-existing LVV.  Thus, we recommend the use of vascular US in all patients with PMR suffering a relapse to investigate the possible co-existence of LVV.


Disclosure:

S. Chrysidis,
None;

P. R. Lage-Hansen,
None;

A. P. Diamantopoulos,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/polymyalgia-rheumatica-relapse-and-silence-large-vessel-vasculitis-is-there-any-association/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology